Early Aubagio ‘preferable for preventing disease progression’
Early Aubagio reduces disability progression more significantly than delayed treatment in patients with multiple sclerosis (MS), according to results from the phase three TOWER study and its open-label extension phase, presented at the 2015 Annual Meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)... Read more - http://www.ms-uk.org/MSnews
Early Aubagio ‘preferable for preventing disease progression
Early Aubagio ‘preferable for preventing disease progression
MS-UK - http://www.ms-uk.org/